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Abstract
Background: The closure of long-standing gaps in our knowledge of aetiological factors behind anti-neutrophil cytoplasmic
antibody (ANCA)-associated vasculitis (AAV) is a major challenge. Descriptive and analytical epidemiological studies can
improve our understanding of environmental influences. Reported seasonal variations in AAV, mainly related to Wegener’s
disease, have shown an increasing number of cases in the winter months, which could be related to an extrinsic factor
underlying infection. The objective of this paper was to study seasonal variations in AAV with respect to renal affectation
diagnosed in Catalonia, Spain.
Methods: Two hundred and thirty-four patients diagnosed for renal AAV between 2001 and 2014 in eight hospitals in
Catalonia were included in the study. We used medical records to retrospectively analyse the date of the first symptoms
attributed to the AAV, ANCA subtypes, the degree of renal impairment and renal histology.
Results: Of the 234 patients studied, 49.2% were male and 50.8% female. For ANCA status, 8.5% were positive, 15.9% were
proteinase-3-positive and 75.6% were myeloperoxidase-positive. In relation to histological classification, 17.8% were
sclerotic, 11.7% focal, 38.8% crescentic and 31.7% mixed. Regarding seasonal distribution, we observed a clear seasonal
periodicity with a significantly higher incidence of cases in the winter. Applying an Eigen decomposition, we observed a
periodic fluctuation of frequencies around the annual cycle with peaks every 10–12 months, and higher incidence of AAV
cases in February.
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Conclusions: Our results confirm, in Catalonia, the seasonal periodicity of AAV with a higher incidence in the winter, as formerly
described in the literature for other regions. An environmental factor, likely one that is infectious, may explain this finding.
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Introduction
Anti-neutrophil cytoplasmic antibody (ANCA)-associated
vasculitis (AAV) comprises three different clinical entities—
granulomatosis with polyangiitis (GPA), microscopic polyangiitis
(MPA) and eosinophilic granulomatosis with polyangiitis—a group
of systemic diseases that are characterized by pauci-immune nec-
rotizing inflammation of small to medium vessels. Present in
most patients, ANCAs against proteinase-3 (PR3) or myeloperoxi-
dase (MPO) are often associated with GPA and MPA, respectively
[1]. AAV affects multiple organ systems, with glomerulonephritis
and pulmonary involvement being frequent manifestations. AAV
is currently defined as a rare autoimmune disease with a current
annual incidence of 20/million/year [2], with increasing incidence
in recent years [3]. The incidence of PR3-AAV and MPO-AAV varies
worldwide. In general, MPO-AAV is seen more frequently in south-
ern Europe, Asia and the Pacific (except in New Zealand and
Australia), while PR3-AAV is more common in the northern coun-
tries of the world [4–7]. In Spain, a study of 450 patients with AAV
found the proportions of entities to be 40.9% for GPA, 37.1% for
MPA and 22% for eosinophilic granulomatosis with polyangiitis
[8]. In another study, which analysed 151 patients with AAV and
renal involvement, proportions of 39.7% for MPA, 6.6% for GPA
and 53.6% for renal limited vasculitis were found [9].
The aetiology of AAV is currently unknown, and so too are the
contributions of genetic and environmental factors to its develop-
ment. Over the past few years, genetic factors contributing to
AAV have been extensively studied, mostly by genome-wide as-
sociation studies. These have demonstrated that patients with
PR3-ANCA have significant association with human leukocyte
antigen (HLA)-DP, and with genes encoding a1-antitrypsin (Serpin
Family A Member 1 (SERPINA1), the endogenous inhibitor of PR3)
and PR3 (proteinase 3; PRTN3). On the other hand, patients with
MPO-ANCA have significant association with HLA-DQ [8].
In relation to environmental factors, previous studies have
demonstrated an increased incidence of AAV in patients exposed
to a variety of air pollutants (e.g. silica) [9], after treatment with
drugs such as penicillamine and hydralazine [10, 11], and in rela-
tion to infectious organisms like a nasal colonization with
Staphylococcus aureus in GPA patients [12]. Supporting the idea of
an underlying infectious factor, several studies have shown that
the onset of AAV varies by season, with incidence peaking in the
winter [13–17]. In clear contrast, a recent study suggested that
AAV appears preferentially in the summer in GPA patients [18],
supporting the idea of a possible allergic mechanism in its patho-
genesis. In addition, in other primary systemic vasculitis condi-
tions, such as Kawasaki disease, a seasonal pattern and possible
environmental triggers have been shown [19, 20].
In the present study, we re-examined the hypothesis of sea-
sonal variations in the onset of renal AAV in a Mediterranean
area in Spain.
Materials and methods
This retrospective study included 234 patients diagnosed with AAV
with renal involvement between January 2001 and December 2014
in eight different hospitals in Catalonia, Spain. Diagnosis of renal
vasculitis was made by according to the criteria established at the
Chapel Hill Conference [21], as determined by positive ANCA (MPO
or PR3) antibodies and a renal biopsy with the presence of necrotiz-
ing pauci-immune glomerulonephritis.
Information regarding the following demographics were ob-
tained from medical records: age, gender, disease features, the date
of first symptoms attributed to the AAV, date of diagnosis, ANCA
subtype, the degree of renal impairment and renal histology classi-
fication. Renal pathology was classified according to the Berden
classification as follows: focal, crescentic, mixed or sclerotic [22].
Related to the date of the first AAV symptoms, we included
onset data for general symptoms such as fever, malaise and/or
weight loss or specific organ involvement, and ear, nose and
throat, pulmonary, renal, ophthalmological and cutaneous in-
volvement. The disease onset–diagnosis interval was calculated
as the difference between the onset of symptoms and the initia-
tion of AAV treatment. For these calculations, onset data were
arbitrarily set as the 15th day of the respective month, unless
patients were able to specify the exact week or day of disease
onset. Finally, we excluded 11 patients because a precise month
of the onset of AAV could not be calculated.
Data analysis was performed using GraphPad Prism 6.0
(GraphPad Software, San Diego, CA, USA). The distribution of
symptom onset according to month and season was examined
for uniformity using exact one-way goodness-of-fit chi-square
tests as a means to identify significant deviations from ex-
pected frequencies. Seasons were divided into spring (April–
June), summer (July–September), autumn (October–December)
and winter (January–March).
An Eigen decomposition was applied to the ANCA time se-
ries with the covariance matrix equivalent of processing a for-
ward–backward prediction data matrix by signal strength rather
than by frequency. Due to the low signal-to-noise ratio in the
epidemiological time series, it was possible in this way to isolate
individual oscillatory components embedded in signals. In this
decomposition, the first eigenvalue, corresponding to seasonal-
ity, accounts for 6.5% of the normalized variability. To further
cross-validate this result, the series of cases was accumulated
and then detrended by a linear least squares approximation.
Comparisons of seasonal distribution patterns for patient
groups (sex, ANCA subtype, degree of renal impairment and re-
nal histology classification) were performed using a chi-square
test. Regarding renal impairment, we divided patients into two
different groups based in their baseline serum creatinine: group
1, <500 lmol/L; and group 2, 500 lmol/L. Regarding histology
classification, we also divided the patients into two different
groups: the first one included patients with crescentic, focal and
mixed classification; and the second one included only patients
with sclerotic classification. This decision was based on the fact
that patients with sclerotic lesions usually have a more impre-
cise date of first symptoms of disease.
Results were considered significant when P< 0.05 and data
are expressed as mean 6 standard error of the mean.
Written informed consent was considered not to be neces-
sary for the study, as it was a retrospective analysis of our usual
everyday work. The data of the patients were anonymized for
the purposes of this analysis. The confidential information of
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the patients was protected according to national norms. This
manuscript has been approved for publication by the Clinical
Research Ethics Committee of Bellvitge University Hospital.
Results
Characteristics of the study population
The main characteristics of our patients at AAV diagnosis are
summarized in Table 1. Most of the 234 patients (around 88%)
lived in the city of Barcelona or in its metropolitan area, with a
predominance of an urban and Caucasian population.
Regarding the demographic characteristics, 49.2% were male
and 50.8% female; 15.9% were PR3-ANCA-positive, 75.6% MPO-
ANCA-positive and 8.5% ANCA-negative. For renal impairment,
the mean baseline serum creatinine at the diagnosis was 422.93
lmol/L (range 62–1418). In respect of histological classification,
17.8% were sclerotic, 11.7% focal, 38.8% crescentic and 31.7%
mixed. The mean onset–diagnosis interval calculated was 3.15
months (range 0.1–45.5).
Monthly and seasonal variations of AAV onset
Monthly and seasonal distributions of AAV onset are shown in
Figure 1. Frequency of disease onset according to month
showed a higher incidence in January, February and March, but
there were no significant variations.
Regarding seasonal distribution, we observed a significantly
higher incidence of cases in the winter and this variation was
significant when compared with the seasonal distribution re-
ported in ANCA MPO-positive patients (chi-square ¼ 13.36, 3 de-
grees of freedom, P¼ 0.003) [17].
Applying an Eigen decomposition, we observed periodic fluc-
tuation of the frequencies with peaks every 10–12 months
around the annual cycle, and a greater incidence of AAV cases
in February (Figure 2).
Using stratification of selected variables (sex, ANCA subtype,
degree of renal impairment and renal histology classification),
no significant differences were found in the analyses of sea-
sonal patterns (Table 2).
Seasonal variations of AAV onset related to geographic
location
In our study, we included patients from eight different hospitals
and areas were as follows: one was urban, located in the city of
Barcelona (Area 1, n ¼ 97); two were located in the metropolitan
area of Barcelona (Area 2, n¼ 70 and Area 3, n¼ 39; located west
and east of Barcelona, respectively); two were located northeast
of Catalonia (Area 4, n ¼ 22); and one was located north-west of
Catalonia (Area 5, n¼ 6).
When we analysed the seasonal variation of AAV related to
geographic location, we found that patients from Barcelona and
the western metropolitan area had similar patterns, with more
homogenous distribution across the seasons. On the other hand,
patients from the east or north-east of Barcelona had a higher in-
cidence of AAV in the winter, whereas patients from the north-
west had higher incidence in spring and summer (Figure 3).
Discussion
AAV needs to be understood as a multifactorial disease that re-
sults from environmental triggers affecting genetically
predisposed individuals. Investigating the effects of seasonal
climate and geographical variations on the onset of this disease
could provide indirect information about its pathogenesis.
Our study re-examined the hypothesis of seasonal variation
in the onset of AAV in a Mediterranean area in north-east Spain
and demonstrated higher incidence of AAV patients with renal
affectation during the winter, supporting several previous stud-
ies that have found similar results [13–17]. This could be linked
to a higher incidence of airway disease in this season, and sub-
sequent respiratory infection factors may trigger the disease, as
described previously [23]; however, our study could not provide
support this proposed link.
Table 1. AAV patient characteristics
Variables Baseline characteristics
Age, mean (SD), years 65.33 (16–89)
Sex (M/F), % 49.2/50.8
Baseline creatinine, mean (range), lmol/L 422.93 (51–1418)
<500 lmol/L, % 67.5
>500 lmol/L, % 32.5
ANCA subtype
Negative, n (%) 20 (8.5)
Anti-MPO, n (%) 177 (75.6)
Anti-PR3, n (%) 37 (15.9)
Histology classification
Focal, n (%) 26 (11.8)
Crescentic, n (%) 85 (38.6)
Mixed, n (%) 70 (31.8)
Sclerotic, n (%) 39 (17.8)
Fig. 1. Distribution of months (A) and season (B) of AAV onset for 234 patients.
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In addition, we demonstrated a periodic seasonal fluctuation
related to the incidence of AAV, with peaks every 10–12 months
around the annual cycle. Tidman et al. [17] previously described
periodic fluctuations in patients with AAV over a period of 21
years; however, these peaks occurred around every 3–4 years.
This difference could be related to the shorter period of our
study compared with that of Tidman et al.
Of note, most of the previous studies were performed in pop-
ulations that included mostly GPA- or PR3-ANCA-positive pa-
tients that do not match with our cohort, which was
predominantly composed of MPO-ANCA-positive patients. Only
one study analysed seasonal variations in a population of MPO-
ANCA patients [17] and found that very few of them presented
with onset of the disease during the summer (14%), with a simi-
lar distribution across the other seasons. In our cohort, fewer
patients presented with MPO-ANCA in the summer, but this as-
sociation was not statistically significant.
With regard to ANCA subtypes, we found lower incidence in
the spring for patients who were ANCA-negative, with only one
patient’s (5%) symptoms initiating during this season. Although
ANCA positivity is noted in more than 90% of AAV patients, several
studies have observed negative ANCA in 10–20% of cases [24–28].
Clinically, the majority of these cases are limited to kidney affecta-
tion with a lower incidence of extra-renal symptoms. A functional
effect of ANCA epitopes or different antibodies [28] (such as anti-
moesin [29], anti-endothelial cells [30] and anti-human lysosome-
associated membrane protein-2 [31]) has been implicated in the
pathogenesis of this disease, but the exact mechanism remains
unclear. The seasonal difference observed between ANCA-positive
and -negative patients in our study supports the idea that these
two entities may have different pathogenic triggers.
Interestingly, when we divided patients according to their
geographic location, higher incidence of AAV was found in the
winter for patients located in areas with similar characteristics
(i.e. the east and north-east of Catalonia). It is possible that an
environmental factor influences the higher incidence of the dis-
ease in these areas in the winter, a subject that deserves further
investigation.
Fig. 2. Evolution of the number of ANCA cases (black) from 2001–14 together with their reconstructed seasonality (red). An Eigen decomposition of order M¼30 was ap-
plied to the raw ANCA time series to maximize the signal extraction process. The inset shows the maximum entropy spectrum derived for this component, showing
two clear significant periods around the annual cycle (11.76 months and 10.12 months, P<0.05).
Fig. 3. Seasonal distribution of AAV patients in different hospitals included in the study. (A) Area 1 (Barcelona), Area 2 (L’Hospitalet de Llobregat), Area 3 (Badalona),
Area 4 (Girona and Palamo´s) and Area 5 (Manresa). (B) The graph shows that patients from Barcelona (Area 1) and the south metropolitan area (Area 2) had similar pat-
terns, with more homogenous distribution across the seasons. On the other hand, patients from the north metropolitan area or the north-east (Areas 3 and 4) had a
greater incidence of AAV in the winter, while patients from the north-west (Area 5) had a greater incidence in the spring and summer.
4 | J. Draibe et al.
Some limitations of this study have to be considered. Since
this study was retrospective and data about the onset of the first
symptoms were obtained from medical records, we have to con-
sider the possibility of recall bias and the difficulty of accurately
determining the moment that this subacute disease first be-
comes apparent. Mahr et al. [18] analysed this problem in their
study, comparing data obtained from medical records and tele-
phone interviews, and found an average discrepancy of about 2.6
months. However, they still found similar results using data col-
lected from medical records. As a result, we discuss here the sea-
sonal nature of symptom presentation rather than the exact
month of occurrence. The other principal limitation of this study
is that only patients with AAV and renal affectation were in-
cluded in this study; despite the large number of patients, this
approach might not be fully representative of AAV in general.
Conclusion
In conclusion, our results in a cohort of AAV patients with renal
affectation in Spain confirm a periodic fluctuation and seasonal
variation of AAV, as described in the literature, with higher inci-
dence in the winter. These results make it plausible that envi-
ronmental factors, most likely an infection trigger, act as
activators for the development of the disease. The seasonal dif-
ferences observed between ANCA-positive and -negative pa-
tients warrant further careful examination.
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